Nivolumab/Ipilimumab in Second Line CUP-syndrome

Sponsor
University Hospital Heidelberg
Study ID
NCT04131621
Phase
PHASE2
Status
Unknown

Conditions

  • Cancer of Unknown Primary Site

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs. Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy. To evaluate the efficacy of nivolumab plus ipilimumab in subjects with poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy

Key Dates

Start date
Dec 12, 2019
Status verified
Apr 2020
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
194 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab/Ipilimumab

Primary Outcome Measure

Progression-free survival [ Time Frame: 3 months ]

Central Contacts

Related Studies